Tempest Therapeutics Inc (TPST)

History and Background

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing small molecule therapeutics that combine both direct tumor-killing and immune-mediated mechanisms. Founded to develop next-generation therapeutics that target different mechanisms than other approaches in immune oncology, Tempest Therapeutics focuses on selectively blocking validated tumor-driving pathways while also stimulating the immune system to attack the tumor.

Core Business Areas

• Oncology Drug Development: Focuses on discovering, developing, and commercializing small molecule therapeutics for cancer treatment.

Leadership and Structure

Dr. Stephen Brady is the CEO. The company has a board of directors and is structured with research and development, clinical operations, and corporate functions.

Key Offerings

• TPST-1120 (PPARu03b1 antagonist): A selective PPARu03b1 antagonist being developed for hepatocellular carcinoma (HCC) and other solid tumors. Currently in Phase 1b/2 clinical trials. Competitors in HCC include drugs from Bayer (BAYRY), Roche (RHHBY), and Bristol Myers Squibb (BMY). Market share data is not currently available for TPST-1120 as it is still in development.
• TPST-1495 (EP2/4 Antagonist): A selective EP2/4 antagonist in preclinical development targeting cancers with high levels of prostaglandin E2 (PGE2). Competitors will depend on the specific indication pursued, but will likely include other immuno-oncology agents. Market share data is not currently available for TPST-1495.

Industry Overview

The oncology market is a large and rapidly growing market driven by an aging population, increasing cancer incidence, and advances in treatment options. Immuno-oncology is a key area of focus.

Positioning

Tempest Therapeutics is positioned as a company developing novel small molecule therapeutics that combine direct tumor-killing and immune-mediated mechanisms, aiming to provide improved outcomes for cancer patients.

Total Addressable Market (TAM)

The global oncology market is estimated to be worth hundreds of billions of dollars. Tempest Therapeutics' TAM depends on the success of its clinical programs and the specific indications pursued. Their positioning within this TAM will depend on future performance of key product candidates.

Key Competitors

• BAYRY
• RHHBY
• BMY
• MRK
• AZN

Competitive Landscape

Tempest Therapeutics faces intense competition from established pharmaceutical companies with significantly greater resources. Its competitive advantage lies in its novel therapeutic approach.

Historical Growth: Historically, growth has been in terms of advancing its pipeline and securing funding.

Future Projections: Future growth depends on successful clinical trials and potential partnerships.

Recent Initiatives: Recent initiatives include advancing the Phase 1b/2 clinical trial of TPST-1120 and progressing TPST-1495 into IND-enabling studies.

Tempest Therapeutics is a high-risk, high-reward clinical-stage company. Its novel approach to cancer treatment offers potential, but its success is highly dependent on clinical trial outcomes and securing funding. It operates in a competitive landscape dominated by larger, established players. Success hinges on proving clinical efficacy and establishing strategic partnerships.

Data Sources:

• Company Website
• SEC Filings
• Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Investing in clinical-stage companies carries significant risk.